Latest news with #Mabwell
Associated Press
27-06-2025
- Business
- Associated Press
Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection
SHANGHAI, June 27, 2025 /PRNewswire/ -- Mabwell ( an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection (R&D code: 8MW0511). Under the terms of the agreement, Mabwell will grant Qilu Pharmaceutical exclusive rights to develop, manufacture, improve, utilize and commercialize the licensed product in the Greater China (including Chinese Mainland, Hong Kong, Macau and Taiwan). T-mab can obtain a total of up to RMB 500 million of upfront payment and sales milestone payment, and the royalty of up to double-digit percentage of net sales of licensed product. Albipagrastim alfa for Injection is a recombinant (yeast-secreted) human serum albumin/human granulocyte-colony stimulating factor (I) fusion protein for Injection. It is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Albipagrastim alfa is a new generation of long-acting G-CSF (highly active modified cytokine) with intellectual property rights of Mabwell, which was developed with albumin fusion platform technology by fusing highly active recombinant G-CSF with human serum albumin (HSA). The modification increases the molecular weight, significantly inhibits the elimination pathway mediated by G-CSF receptor and prolongs the half-life of the drug in vivo, which improves the treatment adherence by reducing the frequency of administration in clinical practice. Compared to PEG-G-CSF, Albipagrastim alfa uses HSA as its natural carrier protein via a Pichia pastoris expression system. This approach offers a simpler production process and superior product homogeneity. About Qilu Pharmaceutical Qilu Pharmaceutical is now one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures and distributes both Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs). Qilu currently has 12 subsidiaries, 11 domestic manufacturing sites and over 36,000 employees worldwide. Qilu ranks among Top 3 in Chinese pharmaceutical industry in 2024. Dedicated to offering high-quality & trustworthy medicines to the world and improving people's well-being, Qilu is vigorously exporting its products to over 100 countries and regions around the world. To date, Qilu has launched over 300 products with over 55 products 'First-to-Launch' in China. The company has also fostered a robust pipeline including over 200 generic products, over 20 biosimilars and over 80 innovative products. Qilu Pharmaceutical is subsidiary of Qilu Pharmaceutical Group Co., Ltd. About Mabwell Mabwell ( is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. The company provides more effective and accessible therapy and innovative medicines to fulfill global medical needs, focusing on oncology and aging-related disease indications. Mabwell's mission is 'Explore Life, Benefit Health' and its vision is 'Innovation, from ideas to reality'. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. 'Forward-looking statements' are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'potential,' 'predict,' 'project,' 'should,' 'would,' and similar expressions and the negatives of those terms. Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company's control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results. The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement. View original content: SOURCE Mabwell
Yahoo
25-04-2025
- Business
- Yahoo
3 Asian Stocks That Could Be Undervalued By Up To 31%
Amidst ongoing global trade tensions and economic uncertainties, Asian markets have shown resilience, with some indices advancing despite challenges such as U.S. tariffs impacting China and Japan's cautious monetary stance. In this environment, identifying undervalued stocks can be key to capitalizing on potential market inefficiencies; a good stock often exhibits strong fundamentals or growth potential that may not yet be fully recognized by the market. Name Current Price Fair Value (Est) Discount (Est) Pegasus (TSE:6262) ¥467.00 ¥917.42 49.1% Micro-Star International (TWSE:2377) NT$133.00 NT$265.36 49.9% Chongqing Zaisheng Technology (SHSE:603601) CN¥3.48 CN¥6.80 48.9% Tongqinglou Catering (SHSE:605108) CN¥20.85 CN¥41.25 49.5% Rise Consulting Group (TSE:9168) ¥921.00 ¥1813.80 49.2% Shanghai HIUV New MaterialsLtd (SHSE:688680) CN¥36.49 CN¥71.51 49% giftee (TSE:4449) ¥1521.00 ¥2981.54 49% Visional (TSE:4194) ¥8334.00 ¥16548.68 49.6% Swire Properties (SEHK:1972) HK$16.44 HK$32.22 49% Bloks Group (SEHK:325) HK$122.60 HK$244.78 49.9% Click here to see the full list of 272 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Overview: Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical company involved in the research, development, manufacture, and commercialization of biological products both in China and internationally, with a market cap of CN¥9.08 billion. Operations: The company generates revenue primarily from its Pharmaceuticals segment, which amounted to CN¥199.78 million. Estimated Discount To Fair Value: 20.6% Mabwell (Shanghai) Bioscience is trading at CN¥22.72, over 20% below its estimated fair value of CN¥28.61, suggesting potential undervaluation based on cash flows. The company forecasts robust revenue growth of 59.5% annually, outpacing the market average and indicating strong future cash flow potential despite a current net loss of CN¥1.07 billion for 2024. Recent clinical advancements in ADCs underscore Mabwell's strategic focus on oncology innovation, which could enhance long-term profitability prospects. The growth report we've compiled suggests that Mabwell (Shanghai) Bioscience's future prospects could be on the up. Click here to discover the nuances of Mabwell (Shanghai) Bioscience with our detailed financial health report. Overview: Shengyi Electronics Co., Ltd. focuses on the research, development, production, and sales of various printed circuit boards in China with a market cap of CN¥20.20 billion. Operations: Shengyi Electronics Co., Ltd. generates revenue through its research, development, production, and sales of various printed circuit boards in China. Estimated Discount To Fair Value: 20.1% Shengyi Electronics, trading at CN¥24.74, is over 20% below its estimated fair value of CN¥30.95, reflecting potential undervaluation based on cash flows. The company recently became profitable with a net income of CN¥331.97 million for 2024, reversing the previous year's loss. Forecasts indicate earnings growth significantly outpacing the market at nearly 40% annually, despite revenue growth being slower than 20%. Recent inclusion in the FTSE All-World Index highlights its growing market presence. Insights from our recent growth report point to a promising forecast for Shengyi Electronics' business outlook. Dive into the specifics of Shengyi Electronics here with our thorough financial health report. Overview: Chugin Financial Group Inc., with a market cap of ¥275.79 billion, operates through its subsidiary The Chugoku Bank, Limited to offer a range of financial services to both corporate and individual clients in Japan. Operations: Chugin Financial Group Inc. generates revenue through its subsidiary, The Chugoku Bank, Limited, by offering diverse financial services to both corporate and individual customers in Japan. Estimated Discount To Fair Value: 31% Chugin Financial Group, Inc. is trading at ¥1,541.5, over 30% below its estimated fair value of ¥2,234.95, indicating potential undervaluation based on cash flows. The company projects ordinary revenues of ¥212 billion and profit attributable to owners of parent at ¥25 billion for the fiscal year ending March 31, 2025. Despite a highly volatile share price recently and a low return on equity forecast (6.7%), revenue growth is expected to outpace the Japanese market significantly at 22.6% annually. The analysis detailed in our Chugin Financial GroupInc growth report hints at robust future financial performance. Click to explore a detailed breakdown of our findings in Chugin Financial GroupInc's balance sheet health report. Access the full spectrum of 272 Undervalued Asian Stocks Based On Cash Flows by clicking on this link. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:688062 SHSE:688183 and TSE:5832. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
